Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 5, 2026.
Q2 2026
EPS
-$3.06
est -$2.06
-48.8%
Revenue
—
est $15M
—
The FDA has accepted the pancreatic cancer application for daraxonrasib, and a $151 million non-cash warrant charge drove most of the 49% miss on expectations. With $3.94 billion in cash, this pre-revenue company is funding a first commercial launch. Next catalysts: Phase 3 RASolve 307 in Q4, updated colorectal data.